**Supplementary Figure 1. BH3 Profiling representative patient data.** Representative BH3

profiling on clinical response (CR) AML patient specimens (A and B) or representative BH3

profiling on non-responder (NR) AML patient specimens ( C. and D.) Seven-digit numbers

represent internal blinded patient ID tracking codes. The complete peptide panel is shown in all

graphs. Higher % priming, notably of BIM(0.1), correlates with better clinical response. Error

bars represent CV of duplicates samples from individual patients.

## Supplementary Figure 1. BH3 Profiling representative patient data



A. AML 3008430

B. AML 3049182

C. AML 3112890

D. AML 3319184

**Supplemetary Figure 2.  BH3 Profiling for BH3 Peptides in AML NR and CR Patients.**  Response discrimination of BH3 profiling of BIM(100), PUMA, PUMA(10), NOXA, BAD, BMF, HRK and PUMA2A is depicted.  Note there is wide spread of individual patient specimen priming scores utilizing the majority of the dynamic range (0% to 100%).   Of these biomarkers and analysis, only PUMA(10) achieves statistical significant correlation with response (p=0.0064).

Supplementary Figure 2.  BH3 Profiling for BH3 Peptides